Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759525 · ClinicalTrials.gov registry record · Phase 2
The Role of Mineralocorticoid Receptors in Vascular Function
A Phase 2 study of Apparent Mineralocorticoid Excess (AME), sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00759525: Completed Phase 2 study of Apparent Mineralocorticoid Excess (AME), sponsored by Brigham and Women's Hospital.
NCT00759525 is a Phase 2 study of Apparent Mineralocorticoid Excess (AME) that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00759525, a Phase 2 study of Apparent Mineralocorticoid Excess (AME), has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to figure out how decreasing the activity of 11-beta hydroxysteroid dehydrogenase (11-beta HSD) will affect your blood vessel function. 11-beta HSD, which is found in the kidneys and blood vessels, is a natural protein that when active helps to keep your blood pressure under control.
Primary Outcome
At the end of each 14-day intervention (Glycyrrhinitic acid or Placebo), vascular endothelial function was assessed by measuring forearm blood flow and comparing to Baseline. The outcome measure depicted below reflects the change in forearm blood flow from Baseline after completing the glycyrrhinitic acid regimen as well as the change in forearm blood flow from Baseline after taking the matching placebo.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Glycyrrhetic Acid
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2002-02 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
What the finished NCT00759525 record still lists
NCT00759525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Apparent Mineralocorticoid Excess (AME) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00759525 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00759525 about?
NCT00759525 is a clinical study titled "The Role of Mineralocorticoid Receptors in Vascular Function". The purpose of this study is to figure out how decreasing the activity of 11-beta hydroxysteroid dehydrogenase (11-beta HSD) will affect your blood vessel function. 11-beta HSD, which is found in the kidneys and blood vessels, is a natural protein that when active helps to keep your blood pressure u...
What is the current status of trial NCT00759525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2002-02. Estimated completion is 2009-09.
What conditions does trial NCT00759525 study?
This clinical trial studies the following conditions: Apparent Mineralocorticoid Excess (AME).
What interventions are being tested in trial NCT00759525?
The interventions under investigation include: Placebo (DRUG), Glycyrrhetic Acid (DRUG).
Who is sponsoring clinical trial NCT00759525?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00759525 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00759525's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia